David E. Goldstein

Prevalence of Diabetes, Impaired Fasting Glucose, and Impaired Glucose Tolerance in U.S. Adults: The Third National Health and Nutrition Examination Survey, 1988–1994

OBJECTIVE To evaluate the prevalence and time trends for diagnosed and undiagnosed diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults by age, sex, and race or ethnic group, based on data from the Third National Health and Nutrition Examination Survey, 1988–1994 (NHANES 111) and prior Health and Nutrition Examination Surveys (HANESs). RESEARCH DESIGN AND METHODS NHANES III contained a probability sample of 18,825 U.S. adults ≥20 years of age who were interviewed to ascertain a medical history of diagnosed diabetes, a subsample of 6,587 adults for whom fasting plasma glucose values were obtained, and a subsample of 2,844 adults between 40 and 74 years of age who received an oral glucose tolerance test. The Second National Health and Nutrition Examination Survey, 1976–1980, and Hispanic HANES used similar procedures to ascertain diabetes. Prevalence was calculated using the 1997 American Diabetes Association fasting plasma glucose criteria and the 1980–1985 World Health Organization (WHO) oral glucose tolerance test criteria. RESULTS Prevalence of diagnosed diabetes in 1988–1994 was estimated to be 5.1% for U.S. adults ≥20 years of age (10.2 million people when extrapolated to the 1997 U.S. population). Using American Diabetes Association criteria, the prevalence of undiagnosed diabetes (fasting plasma glucose ≥126 mg/dl) was 2.7% (5.4 million), and the prevalence of impaired fasting glucose (110 to <126 mg/dl) was 6.9% (13.4 million). There were similar rates of diabetes for men and women, but the rates for non-Hispanic blacks and Mexican-Americans were 1.6 and 1.9 times the rate for non-Hispanic whites. Based on American Diabetes Association criteria, prevalence of diabetes (diagnosed plus undiagnosed) in the total population of people who were 40–74 years of age increased from 8.9% in the period 1976–1980 to 12.3% by 1988–1994. A similar increase was found when WHO criteria were applied (11.4 and 14.3%). CONCLUSIONS The high rates of abnormal fasting and postchallenge glucose found in NHANES III, together with the increasing frequency of obesity and sedentary lifestyles in the population, make it likely that diabetes will continue to be a major health problem in the U.S

Report of the American Diabetes Association's Task Force on Standardization of the Insulin Assay

Recent large-scale epidemiological studies demonstrate that blood concentrations of immunoreactive insulin predict the development of NIDDM and IDDM and are associated with the risk of several degenerative diseases, such as coronary and peripheral vessel atherosclerosis, hypertension, and dyslipidemia. The reliability of these measurements is dependent on a biological assay that has not been well standardized between laboratories. Recognizing this, the American Diabetes Association organized a task force to assess comparability of blood insulin measurements between laboratories and to suggest techniques to improve comparability. The task force found that identical serum and plasma samples measured in different laboratories produced widely disparate values that were unacceptable for population comparisons. Use of a single reference standard did little to improve comparability. Assay characteristics such as linearity, recovery, accuracy, and cross-reactivity to proinsulin and its primary conversion intermediates varied among the laboratories, and they did not readily explain differences in the measurements made from assay to assay. Use of the same assay kit in different laboratories did not always ensure comparable measurements. Linear regression of assay results from one laboratory to an arbitrarily chosen reference assay greatly improved comparability and demonstrated the potential value in comparing each assay to a reference method. The task force report defines acceptable assay characteristics and proposes a three-step process of insulin assay proficiency and comparability. A central reference assay and ongoing sample exchange will be needed to allow reliable comparisons of insulin measurements made in different laboratories. Rigorous quality control and continuous quality improvement are needed to maintain reliability of the insulin measurement.

Clinical Application of Glycosylated Hemoglobin Measurements

Glycosylated hemoglobin measurement has been shown to be a potentially useful tool for both a variety of research applications and for the management of patients with diabetes mellitus. None of the methods available to quantitate glycosylated hemoglobins is ideal. We have reviewed a number of critical methodologie considerations for Chromatographie procedures including the effects of sample storage under various conditions, and the importance of removing labile components prior to analyses. We have developed a method for the colorimetrie determination of glycosylated hemoglobins that is more rapid than methods reported previously, that correlates well with results using high-performance liquid chromatogra-phy, and that can he standardized between laboratories. We have reviewed our experience using glycosylated hemoglobin in a large population of diabetic youths. We have presented a method for developing realistic goals for glucose control using glycosylated hemoglobin and for using glycosylated hemoglobin as a patient education and care reinforcement tool.

Effects of Acute Changes in Blood Glucose on HbA1c

SUMMARY Although hemoglobin A1c (HbA1c) is generally considered to be an accurate index of long-term blood glucose regulation, several recent studies suggest that HbA1c may be acutely responsive to changes in blood glucose. We have examined the effects of acute changes in glucose concentration in vivo and in vitro on HbA1c. HbA1c was measured by a high-performance liquid chromatography (HPLC) method. HbA1c and plasma glucose were measured in seven diabetic patients and five control subjects before and 2 h after a standard breakfast. Only diabetic patients showed increases in HbA1c and plasma glucose values 2 h after the test meal (Δ HbA1c = 0.87 ± 0.24% and Δ glucose = 210 ± 0.33 mg/dl). The increment in HbA1c correlated significantly with the increment in plasma glucose (r = 0.73, P < 0.05). to examine the lability of these postmeal increments in HbA1c, erythrocytes from pre- and postmeal blood samples were incubated in 0.9% NaCl for 5 h at 37°C and HbA1c was re-measured. After saline incubations %HbA1c in pre- and postmeal blood samples decreased in both diabetics and controls, and from each subject time 0 and 2-h HbA1c values were nearly identical. HbA1c was then measured before and after incubations of erythrocytes from a larger group of diabetic patients (N = 55) and control subjects (N = 7). In both diabetic and control cells HbAlc decreased after saline incubations. Pre- and post-saline HbA1c values in diabetics were (means ± SEM) 10.07 ± 0.30% and 9.15 ± 0.27%, respectively; values in controls were 5.87 ± 0.11% and 5.46 ± 0.09%, respectively. The mean decrement in HbA1c was significantly greater in cells from diabetics than from controls (P < 0.001). In diabetics the HbA1c decrement correlated with both plasma glucose (r = 0.58, P < 0.001) and the preincubation HbA1c (r = 0.55, P < 0.001). After dialysis of hemolysates for 5 h at 37°C or 48–72 h at 4°C, HbA1c values showed decreases comparable to those after saline incubations of intact erythrocytes. However, decreases in HbA1c after dialysis were accompanied by increases in HbA1a+b, findings that were not observed after saline incubation. The results suggest that HbA1c exists in two chromatographically indistinguishable forms: one that represents the major portion of HbA1c in normals and diabetics, is not altered by short-term changes in plasma glucose, and can be estimated by measuring HbA1c after saline incubation of erythrocytes; and a second form that is responsive to short-term fluctuations of the blood glucose level. These labile and stable fractions may be identical to the labile Schiff-base and stable ketoamine forms of HbA1c, which have been previously described. For HbA1c to be an accurate indicator of long-term glucose control, saline incubation of erythrocytes or perhaps dialysis of hemolysates before HbA1c assay may be necessary. Otherwise the assay results will reflect recent changes in blood glucose levels.

Relationship of Glycosylated Hemoglobin to Oral Glucose Tolerance: Implications for Diabetes Screening

The oral glucose tolerance test (OGTT) for diagnosis of diabetes is inconvenient and requires a great deal of patient cooperation. Glycosylated hemoglobin (GHb), an index of long-term glycemic control, could offer several practical advantages over the OGTT for diabetes screening. We evaluated GHb as a screen for diabetes in 381 adults from a population with a high prevalence of non-insulin-dependent diabetes (Pima Indians). All individuals underwent a standard OGTT (75 g) and were separated into one of three groups: normal (N), impaired glucose tolerance (IGT), or diabetes mellitus (D) based on World Health Organization criteria. HbA1c, a GHb, was measured by highly precise high-performance liquid chromatography (interassay C.V. <4%). The normal range for HbA1c was 4.07–6.03% based on the 95% confidence interval for a nondiabetic, mostly Caucasian population. Compared with OGTT, HbA1c was highly specific (91%); an elevated HbA1c usually indicated D or IGT (sensitivity = 85 and 30%, respectively). A normal HbA1c did not, however, exclude a diagnosis of D or IGT. Based on previous epidemiological studies relating plasma glucose to chronic diabetic complications, GHb as measured in this study would properly identify the vast majority of subjects at risk. Long-term studies are necessary to determine the actual risk of complications in individuals with persistently normal HbA1c and D or IGT (based on OGTT).

Comparisons of Studies on Diabetic Complications Hampered by Differences in GHb Measurements

OBJECTIVE To compare glycated hemoglobin (GHb) values of the relationship between glycemic control and complications of diabetes from laboratories involved in long-term studies (Steno, Oslo, Stockholm, Diabetes Control and Complications Trial, and Linköping.) RESEARCH DESIGN AND METHODS Blood samples were collected from 25 subjects selected to represent the clinically relevant measurement range. Fresh whole-blood samples were distributed and analyzed within 4 days of sample collection. Pretreatment of samples and analyses of GHb were performed according to the routine method of each studys central or reference laboratory. Results from each laboratory were compared with the group mean, i.e., the mean of all results for each sample. RESULTS Regression analyses with the group mean values as independent variables and results from each laboratory as dependent variables showed that Oslos result had a slope significantly different from the group mean. Laboratories used by the DCCT, Oslo, and Steno studies gave, on average, 0.4, 0.4, and 0.7% higher HbA1c readings than the group mean, respectively, while HbA1c results from Linköping and Stockholm were, on average, 0.6 and 1.0% lower, respectively. CONCLUSIONS There were large differences in GHb values among laboratories participating in studies of diabetic complications. The present data offer a guide to the comparison of results from the studies and underscores the need for standardization of GHb measurements.

A Prospective Study of Symptomatic Hypoglycemia in Young Diabetic Patients

The frequency of symptomatic hypoglycemia was determined prospectively over an 18-mo period in 147 children and adolescents with diabetes mellitus. All patients were treated with two daily injections of insulin. The data were analyzed to determine the relationship between episodes of symptomatic hypoglycemia and blood glucose control as assessed by hemoglobin A1c measurements. There were 542 patient visits during the study period. During each clinic visit, patients were separated into one of four hypoglycemic categories based on the medical history since the preceding visit. These categories were: no reactions, mild to occasional reactions, mild to frequent reactions, and severe reactions. Reactions were considered severe if they were characterized by altered central nervous system function or prolonged sympathetic nervous system symptoms. Forty-seven percent of the patients reported at least one reaction during the 18-mo study period, but only 4% (i.e., 6 out of 147 patients) reported severe reactions. The mean hemoglobin A1c level was significantly lower in patients who reported reactions than in patients who did not report reactions [hemoglobin A1c values (x¯ ± SEM) = 7.78 ± 0.1% vs. 9.48 ± 0.1%, respectively; P > 0.001]. The severity of hypoglycemia was inversely related to the degree of altered blood glucose control; episodes of frequent or severe symptomatic hypoglycemia occurred almost exclusively in patients with well-controlled diabetes as reflected in their near-normal hemoglobin A1c levels. There were no significant differences in mean insulin dose/kg, age, or duration of diabetes comparing patients in the four hypoglycemic categories. The results indicate that the hemoglobin A1c level can be a useful clinical guide to identify patients who are most likely to develop serious symptomatic hypoglycemia.

The Relationship Between Psychological Factors and Blood Glucose Regulation in Insulki-dependent Diabetic Adolescents

Fifty-two insulin-dependent diabetic, white, rural, middle-class adolescent subjects who had diabetes 5 or more years participated in a project comparing psychological and personality variables to the degree of altered blood glucose regulation as measured by hemoglobin A1c (HbA1c) levels. An HbA1c level of 9.5% was arbitrarily chosen as a cutoff score to divide subjects into two groups: those having “adequate” (N = 25) and those having “inadequate” (N = 27) blood glucose regulation. There were no significant differences between high and low HbA1c groups for all psychological variables tested, i.e., anxiety, locus of control, self-concept, and various personality traits measured by the High School Personality Questionnaire (HSPQ). Female subjects scored significantly higher on the anxiety scale and had significantly higher HbA1c values and weight percentiles compared with male subjects. Six self-report diabetes questionnaires dealing with various aspects of diabetes care and adjustment were completed by mothers and five similar questionnaires were completed by the adolescents. There were no significant differences in the mean scores of the 11 diabetes questionnaires between the high and low HbA1c groups. Girls scored significantly higher than boys in “self-care” and on individual items pertaining to dysphoric feelings about diabetes. Our findings may have resulted from the homogeneity of the sample, but underlying metabolic and genetic factors need to be considered in differentiating subjects according to the level of blood glucose regulation.

High Prevalence of Echocardiographic Abnormalities in Diabetic Youths

M-mode echocardiography was performed on 107 young insulin-dependent diabetic subjects aged 2 – 24 yr (± SE: 13.8 ± 0.4 yr) and 636 age-group-matched controls. All patients were normotensive and free of cardiorespiratory symptoms. Diabetic patients showed a high prevalence of echocardiographic abnormalities that increased with age. Mean dimensions of the left atrium, right ventricle, and left ventricle (systolic and diastolic) were increased significantly in diabetic individuals (P < 0.01). Hypertrophy of the interventricular septum was present in some patients older than 12 yr of age. Mean interventricular septum excursion was markedly decreased in diabetic individuals compared with controls (3.9 ± 0.1 mm versus 5.6 ± 0.2 mm, respectively; P < 0.01). Fifteen percent of the diabetic patients but none of the controls had septal excursions less than 3 mm (2 SD below mean). Patients with decreased septal excursions showed a higher prevalence of other echocardiographic abnormalities than patients with normal septal excursions. Echocardiographic abnormalities did not correlate with either duration of diabetes or glucose control as assessed by hemoglobin Alc and plasma glucose concentrations at the time of echocardiographic testing. The results show a high prevalence of echocardiographic abnormalities in young diabetic subjects that may represent preclinical cardiomyopathy.

Duchenne muscular dystrophy, glycerol kinase deficiency, and adrenal insufficiency associated with Xp21 interstitial deletion

We report an interstitial deletion in the short arm of the X chromosome in a 6-year-old boy with Duchenne muscular dystrophy, glycerol kinase deficiency, adrenal insufficiency, intermittent hypoglycemia, spasticity, psychomotor retardation, and growth delay. His mother also has this deletion in an X chromosome. From our findings, we propose that the human glycerol kinase locus and the human X-linked adrenal hypoplasia locus are in the Xp21 band.